ADCT (ADC Therapeutics) Tariff Resilience Score : 6/10 (As of Jul. 06, 2025)

View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics Tariff Resilience Score?

ADC Therapeutics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

ADC Therapeutics has ADC Therapeutics relies on global supply chains for drug development. While tariffs on pharmaceuticals are generally low, supply chain disruptions can impact costs. It has some mitigation strategies through alternative suppliers.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes ADC Therapeutics might have Average Resilient.

Competitive Comparison of ADC Therapeutics's Tariff Resilience Score

For the Biotechnology subindustry, ADC Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ADC Therapeutics's Tariff Resilience Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADC Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where ADC Therapeutics's Tariff Resilience Score falls into.

Save Embed

;

Save Embed

;

ADC Therapeutics (NYSE:ADCT) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score	Resilience Level
7 - 10	Highly Resilient
4 - 6	Average Resilient
0 - 3	Highly Vulnerable

ADC Therapeutics Tariff Resilience Score Related Terms

Thank you for viewing the detailed overview of ADC Therapeutics's Tariff Resilience Score provided by GuruFocus.com. Please click on the following links to see related term pages.

ADC Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Tariff Resilience Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066

Website

https://www.adctherapeutics.com

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).